Center for Molecular Engineering (CME)

Associated Partners

InstitutionLocationProjectsCollaborators
University of VirginiaCharlottesville, VADrug Discovery for COPD and IPFMichael Shim
Biomarkers for Diagnosis of IPF Pulmonary diseasesJohn Kim and
Jeffrey Sturek
Virginia Commonwealth UniversityRichmond, VAMed Chem of glycosaminoglycansUmesh Desai
Georgetown UniversityWashington, DCRadiation Biomarkers in biological fluidsEvan Pannkuk
Biomarkers for breast cancer researchMaria Laura Avantaggiati
Virginia TechBlacksburg, VAVEEV viral infection and treatmentsKylene Kehn-Hall
University of PennsylvaniaPhiladelphia, PARNA TherapeuticsMohamed Gabriel
University of ConnecticutStorrs, CTRNA and DNA analysisDaniel Fabris
Ceres Nanosciences, IncManassas, VARetinoic acid from biofermentors QA/QCBen Lepene
Capra Biosciences, Inc.Manassas, VANanoparticles and their applicationsAndrew Magyar
Amerimmune Therapeutics, LLC.Mclean, VACaspase inhibitors for APS therapeuticsOral Alpan
Covenant Therapeutics, LLC.Richmond, VACOPD therapeuticsMichael Borton
Eastern Virginia Medical SchoolNorfolk, VAProstate cancer biomarker discoveryJulius O. Nyalwidhe
National Institute of StandardsRockville, MDStandard Reference material researchThomas Cleveland
Max Planck InstituteBad Nauheim, GermanyPTMs and GlycolipidsMiloslav Sanda

  • *The programs and services offered by George Mason University are open to all who seek them. George Mason does not discriminate on the basis of race, color, religion, ethnic national origin (including shared ancestry and/or ethnic characteristics), sex, disability, military status (including veteran status), sexual orientation, gender identity, gender expression, age, marital status, pregnancy status, genetic information, or any other characteristic protected by law. After an initial review of its policies and practices, the university affirms its commitment to meet all federal mandates as articulated in federal law, as well as recent executive orders and federal agency directives.